Circulating natriuretic peptide concentrations reflect changes in insulin sensitivity over time in the Diabetes Prevention Program

Geoffrey A. Walford, Yong Ma, Costas A. Christophi, Ronald B. Goldberg, Petr Jarolim, Edward Horton, Kieren Mather, Elizabeth Barrett-Connor, Jaclyn Davis, Jose C. Florez, Thomas J. Wang

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Aims/hypothesis: We aimed to study the relationship between measures of adiposity, insulin sensitivity and N-terminal pro-B-type natriuretic peptide (NT-proBNP) in the Diabetes Prevention Program (DPP). Methods: The DPP is a completed clinical trial. Using stored samples from this resource, we measured BMI, waist circumference (WC), an insulin sensitivity index (ISI; [1/HOMA-IR]) and NT-proBNP at baseline and at 2 years of follow-up in participants randomised to placebo (n=692), intensive lifestyle intervention (n=832) or metformin (n=887). Results: At baseline, log NT-proBNP did not differ between treatment arms and was correlated with baseline log ISI (p<0.0001) and WC (p=0.0003) but not with BMI (p=0.39). After 2 years of treatment, BMI decreased in the lifestyle and metformin groups (both p<0.0001); WC decreased in all three groups (p<0.05 for all); and log ISI increased in the lifestyle and metformin groups (both p<0.001). The change in log NT-proBNP did not differ in the lifestyle or metformin group vs the placebo group (p>0.05 for both). In regression models, the change in log NT-proBNP was positively associated with the change in log ISI (p<0.005) in all three study groups after adjusting for changes in BMI and WC, but was not associated with the change in BMI or WC after adjusting for changes in log ISI. Conclusion/interpretation: Circulating NT-proBNP was associated with a measure of insulin sensitivity before and during preventive interventions for type 2 diabetes in the DPP. This relationship persisted after adjustment for measures of adiposity and was consistent regardless of whether a participant was treated with placebo, intensive lifestyle intervention or metformin.

Original languageEnglish
Pages (from-to)935-939
Number of pages5
JournalDiabetologia
Volume57
Issue number5
DOIs
StatePublished - 2014

Fingerprint

Natriuretic Peptides
Brain Natriuretic Peptide
Insulin Resistance
Waist Circumference
Metformin
Adiposity
Life Style
Placebos
Type 2 Diabetes Mellitus
Clinical Trials

Keywords

  • Diabetes prevention
  • Insulin sensitivity
  • Natriuretic peptides
  • NT-proBNP
  • Obesity

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Medicine(all)

Cite this

Walford, G. A., Ma, Y., Christophi, C. A., Goldberg, R. B., Jarolim, P., Horton, E., ... Wang, T. J. (2014). Circulating natriuretic peptide concentrations reflect changes in insulin sensitivity over time in the Diabetes Prevention Program. Diabetologia, 57(5), 935-939. https://doi.org/10.1007/s00125-014-3183-2

Circulating natriuretic peptide concentrations reflect changes in insulin sensitivity over time in the Diabetes Prevention Program. / Walford, Geoffrey A.; Ma, Yong; Christophi, Costas A.; Goldberg, Ronald B.; Jarolim, Petr; Horton, Edward; Mather, Kieren; Barrett-Connor, Elizabeth; Davis, Jaclyn; Florez, Jose C.; Wang, Thomas J.

In: Diabetologia, Vol. 57, No. 5, 2014, p. 935-939.

Research output: Contribution to journalArticle

Walford, GA, Ma, Y, Christophi, CA, Goldberg, RB, Jarolim, P, Horton, E, Mather, K, Barrett-Connor, E, Davis, J, Florez, JC & Wang, TJ 2014, 'Circulating natriuretic peptide concentrations reflect changes in insulin sensitivity over time in the Diabetes Prevention Program', Diabetologia, vol. 57, no. 5, pp. 935-939. https://doi.org/10.1007/s00125-014-3183-2
Walford, Geoffrey A. ; Ma, Yong ; Christophi, Costas A. ; Goldberg, Ronald B. ; Jarolim, Petr ; Horton, Edward ; Mather, Kieren ; Barrett-Connor, Elizabeth ; Davis, Jaclyn ; Florez, Jose C. ; Wang, Thomas J. / Circulating natriuretic peptide concentrations reflect changes in insulin sensitivity over time in the Diabetes Prevention Program. In: Diabetologia. 2014 ; Vol. 57, No. 5. pp. 935-939.
@article{96cbf88946384d7a825d456423ddca48,
title = "Circulating natriuretic peptide concentrations reflect changes in insulin sensitivity over time in the Diabetes Prevention Program",
abstract = "Aims/hypothesis: We aimed to study the relationship between measures of adiposity, insulin sensitivity and N-terminal pro-B-type natriuretic peptide (NT-proBNP) in the Diabetes Prevention Program (DPP). Methods: The DPP is a completed clinical trial. Using stored samples from this resource, we measured BMI, waist circumference (WC), an insulin sensitivity index (ISI; [1/HOMA-IR]) and NT-proBNP at baseline and at 2 years of follow-up in participants randomised to placebo (n=692), intensive lifestyle intervention (n=832) or metformin (n=887). Results: At baseline, log NT-proBNP did not differ between treatment arms and was correlated with baseline log ISI (p<0.0001) and WC (p=0.0003) but not with BMI (p=0.39). After 2 years of treatment, BMI decreased in the lifestyle and metformin groups (both p<0.0001); WC decreased in all three groups (p<0.05 for all); and log ISI increased in the lifestyle and metformin groups (both p<0.001). The change in log NT-proBNP did not differ in the lifestyle or metformin group vs the placebo group (p>0.05 for both). In regression models, the change in log NT-proBNP was positively associated with the change in log ISI (p<0.005) in all three study groups after adjusting for changes in BMI and WC, but was not associated with the change in BMI or WC after adjusting for changes in log ISI. Conclusion/interpretation: Circulating NT-proBNP was associated with a measure of insulin sensitivity before and during preventive interventions for type 2 diabetes in the DPP. This relationship persisted after adjustment for measures of adiposity and was consistent regardless of whether a participant was treated with placebo, intensive lifestyle intervention or metformin.",
keywords = "Diabetes prevention, Insulin sensitivity, Natriuretic peptides, NT-proBNP, Obesity",
author = "Walford, {Geoffrey A.} and Yong Ma and Christophi, {Costas A.} and Goldberg, {Ronald B.} and Petr Jarolim and Edward Horton and Kieren Mather and Elizabeth Barrett-Connor and Jaclyn Davis and Florez, {Jose C.} and Wang, {Thomas J.}",
year = "2014",
doi = "10.1007/s00125-014-3183-2",
language = "English",
volume = "57",
pages = "935--939",
journal = "Diabetologia",
issn = "0012-186X",
publisher = "Springer Verlag",
number = "5",

}

TY - JOUR

T1 - Circulating natriuretic peptide concentrations reflect changes in insulin sensitivity over time in the Diabetes Prevention Program

AU - Walford, Geoffrey A.

AU - Ma, Yong

AU - Christophi, Costas A.

AU - Goldberg, Ronald B.

AU - Jarolim, Petr

AU - Horton, Edward

AU - Mather, Kieren

AU - Barrett-Connor, Elizabeth

AU - Davis, Jaclyn

AU - Florez, Jose C.

AU - Wang, Thomas J.

PY - 2014

Y1 - 2014

N2 - Aims/hypothesis: We aimed to study the relationship between measures of adiposity, insulin sensitivity and N-terminal pro-B-type natriuretic peptide (NT-proBNP) in the Diabetes Prevention Program (DPP). Methods: The DPP is a completed clinical trial. Using stored samples from this resource, we measured BMI, waist circumference (WC), an insulin sensitivity index (ISI; [1/HOMA-IR]) and NT-proBNP at baseline and at 2 years of follow-up in participants randomised to placebo (n=692), intensive lifestyle intervention (n=832) or metformin (n=887). Results: At baseline, log NT-proBNP did not differ between treatment arms and was correlated with baseline log ISI (p<0.0001) and WC (p=0.0003) but not with BMI (p=0.39). After 2 years of treatment, BMI decreased in the lifestyle and metformin groups (both p<0.0001); WC decreased in all three groups (p<0.05 for all); and log ISI increased in the lifestyle and metformin groups (both p<0.001). The change in log NT-proBNP did not differ in the lifestyle or metformin group vs the placebo group (p>0.05 for both). In regression models, the change in log NT-proBNP was positively associated with the change in log ISI (p<0.005) in all three study groups after adjusting for changes in BMI and WC, but was not associated with the change in BMI or WC after adjusting for changes in log ISI. Conclusion/interpretation: Circulating NT-proBNP was associated with a measure of insulin sensitivity before and during preventive interventions for type 2 diabetes in the DPP. This relationship persisted after adjustment for measures of adiposity and was consistent regardless of whether a participant was treated with placebo, intensive lifestyle intervention or metformin.

AB - Aims/hypothesis: We aimed to study the relationship between measures of adiposity, insulin sensitivity and N-terminal pro-B-type natriuretic peptide (NT-proBNP) in the Diabetes Prevention Program (DPP). Methods: The DPP is a completed clinical trial. Using stored samples from this resource, we measured BMI, waist circumference (WC), an insulin sensitivity index (ISI; [1/HOMA-IR]) and NT-proBNP at baseline and at 2 years of follow-up in participants randomised to placebo (n=692), intensive lifestyle intervention (n=832) or metformin (n=887). Results: At baseline, log NT-proBNP did not differ between treatment arms and was correlated with baseline log ISI (p<0.0001) and WC (p=0.0003) but not with BMI (p=0.39). After 2 years of treatment, BMI decreased in the lifestyle and metformin groups (both p<0.0001); WC decreased in all three groups (p<0.05 for all); and log ISI increased in the lifestyle and metformin groups (both p<0.001). The change in log NT-proBNP did not differ in the lifestyle or metformin group vs the placebo group (p>0.05 for both). In regression models, the change in log NT-proBNP was positively associated with the change in log ISI (p<0.005) in all three study groups after adjusting for changes in BMI and WC, but was not associated with the change in BMI or WC after adjusting for changes in log ISI. Conclusion/interpretation: Circulating NT-proBNP was associated with a measure of insulin sensitivity before and during preventive interventions for type 2 diabetes in the DPP. This relationship persisted after adjustment for measures of adiposity and was consistent regardless of whether a participant was treated with placebo, intensive lifestyle intervention or metformin.

KW - Diabetes prevention

KW - Insulin sensitivity

KW - Natriuretic peptides

KW - NT-proBNP

KW - Obesity

UR - http://www.scopus.com/inward/record.url?scp=84898600769&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84898600769&partnerID=8YFLogxK

U2 - 10.1007/s00125-014-3183-2

DO - 10.1007/s00125-014-3183-2

M3 - Article

C2 - 24554005

AN - SCOPUS:84898600769

VL - 57

SP - 935

EP - 939

JO - Diabetologia

JF - Diabetologia

SN - 0012-186X

IS - 5

ER -